{"product_id":"questdiagnostics-bcg-matrix","title":"Quest Diagnostics Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuest Diagnostics’ BCG Matrix preview highlights its core diagnostics services as potential Cash Cows with steady market share, emerging molecular and genomic testing as Question Marks poised for growth, and legacy low-margin segments trending toward Dogs—insights that hint at resource reallocation and R\u0026amp;D prioritization. This concise snapshot suggests strategic focus areas but only scratches the surface; purchase the full BCG Matrix for quadrant-level data, actionable recommendations, and ready-to-use Word and Excel deliverables to guide investment and portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Molecular and Genomic Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuest Diagnostics leads Next-Generation Sequencing (NGS) and precision medicine with \u0026gt;30% U.S. market share in advanced molecular testing by Q4 2025, driven by $420M+ annual R\u0026amp;D and capex in NGS platforms.\u003c\/p\u003e \n\u003cp\u003eThe segment taps double-digit industry growth—~14% CAGR 2022–2026—and rising personalized therapy demand, contributing ~8% of Quest’s 2025 revenue ($8.3B total).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Liquid Biopsy Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe non-invasive cancer screening and monitoring market (liquid biopsy) grew ~28% CAGR to reach about $8.5B globally in 2024 and is forecasted near $15B by 2028; Quest Diagnostics captured a meaningful share by integrating NGS-based and cfDNA assays into labs, adding roughly $350M revenue from oncology testing in FY2024.\u003c\/p\u003e\n\u003cp\u003eThese services demand heavy upfront CAPEX—Quest invested ~ $200M+ in 2023–24 for equipment, lab builds, and partnerships—but they secure pricing power and higher margins in the high-growth oncology diagnostics sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer-Initiated Testing via QuestHealth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestHealth, Quest Diagnostics’ direct-to-consumer digital lab platform, is a BCG Matrix Star due to accelerating patient-centric care; consumer-initiated orders grew ~45% YoY in 2024, driving double-digit digital revenue gains and higher margins versus legacy channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlzheimers and Neurology Biomarkers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuest Diagnostics’ blood-based Alzheimer biomarkers are a 2025 star: revenue growth over 40% YoY as aging populations and new FDA drug approvals (eg, lecanemab, donanemab) boost testing demand.\u003c\/p\u003e\n\u003cp\u003eThe segment is high-growth—global neurodegenerative diagnostics market projected ~$9.5B by 2028—and Quest leads with ~30% US market share in AD biomarker testing and nationwide lab infrastructure for drug rollout.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: if biomarker tests reach 2M patients in 2025 at $350\/test, that’s $700M in annual revenue supporting payer, clinical trial, and retail channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40% YoY revenue growth\u003c\/li\u003e\n\u003cli\u003e~30% US market share\u003c\/li\u003e\n\u003cli\u003e$350 average test price\u003c\/li\u003e\n\u003cli\u003e$700M potential 2025 revenue at 2M tests\u003c\/li\u003e\n\u003cli\u003eGlobal diagnostics market ~$9.5B by 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePopulation Health and Data Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuest Diagnostics’ Population Health and Data Analytics is a Star: revenue from analytics and informatics grew ~18% in 2024, driven by access to \u0026gt;450 million patient records and contracts with 1,800+ health systems and insurers.\u003c\/p\u003e\n\u003cp\u003eAs value-based care expands, demand for predictive models rose; Quest deployed AI models across care pathways, reducing hospital readmissions in pilots by ~12% and saving partners millions in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e450+ million patient records\u003c\/li\u003e\n\u003cli\u003e1,800+ health system\/insurer contracts\u003c\/li\u003e\n\u003cli\u003eAnalytics revenue growth ~18% in 2024\u003c\/li\u003e\n\u003cli\u003eAI pilots cut readmissions ~12% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuest Dominates Precision Diagnostics: NGS, Liquid Biopsy \u0026amp; AD Tests Fuel Rapid Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuest’s Stars: NGS\/precision medicine (\u0026gt;30% US share, $420M+ R\u0026amp;D), liquid biopsy (~$350M oncology revenue FY2024; global market $8.5B 2024 → ~$15B 2028), AD biomarkers (30% US share; \u0026gt;40% YoY growth; $700M potential at 2M tests@ $350), QuestHealth DTC (+45% consumer orders 2024), Population Health (450M records; 18% analytics growth).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$420M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology rev FY2024\u003c\/td\u003e\n\u003ctd\u003e$350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAD test price\u003c\/td\u003e\n\u003ctd\u003e$350\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAD rev potential 2025\u003c\/td\u003e\n\u003ctd\u003e$700M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient records\u003c\/td\u003e\n\u003ctd\u003e450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix overview of Quest Diagnostics: identifies Stars, Cash Cows, Question Marks, and Dogs with strategic investment, hold, or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Quest Diagnostics units into clear quadrants for quick C-level decisions and presentation-ready export.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine Clinical Laboratory Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard blood work and metabolic panels remained the bedrock of Quest Diagnostics’ financial stability at end-2025, delivering roughly $4.1 billion in revenue and ~38% operating margin for core lab testing in FY2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmployer Drug Testing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuest Diagnostics holds roughly 30–35% share of the US workplace drug-testing market (2024 estimate), a dominant slot in a low-growth sector (~2% CAGR), delivering steady volumes from long-term corporate contracts and consortium accounts.\u003c\/p\u003e\n\u003cp\u003eThese employer screening services run high throughput labs with EBITDA margins near 20% (2024), producing predictable free cash flow that funds interest payments and dividends—Quest paid $1.02B in dividends and debt service in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician Office Laboratory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy serving thousands of outpatient clinics, Quest Diagnostics' Physician Office Laboratory Services holds a dominant market share in a low-growth segment—roughly 25–30% share nationwide as of 2024—classifying it as a cash cow in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eIntegrated billing, courier routes, and EMR connections create high switching costs for providers, locking in recurring revenue that contributed about $2.1 billion in segment operating income in 2024.\u003c\/p\u003e\n\u003cp\u003eManagement emphasizes operational efficiency—route densification, lab automation, and yield optimization—to boost margins; a 2024 productivity push cut per-sample cost by an estimated 6%, freeing cash for capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExclusive and preferred-provider agreements with insurers like UnitedHealthcare drive steady revenue for Quest Diagnostics, with insurer-contracted volumes representing an estimated 40–50% of patient tests in 2024, producing high-margin, repeatable cash flows despite low market growth.\u003c\/p\u003e\n\u003cp\u003eLong-term contracts lock in network access and referral volumes, supporting consistent profitability: Quest reported adjusted operating margin ~17% in 2024, helped by these managed-care relationships.\u003c\/p\u003e\n\u003cp\u003eGrowth is limited by market saturation and payer consolidation, so reinvestment focuses on efficiency and service retention rather than expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInsurer volumes ~40–50% (2024)\u003c\/li\u003e\n\u003cli\u003eAdj. operating margin ~17% (2024)\u003c\/li\u003e\n\u003cli\u003eLow growth, high share = steady cash flow\u003c\/li\u003e\n\u003cli\u003eFocus: efficiency and retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Immunodiagnostics and Allergy Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTesting for common infectious diseases and allergies is a mature, high-margin segment for Quest Diagnostics, with routine panels generating steady revenue—Quest reported $9.3B revenue in 2024, and basic immunodiagnostics likely contribute ~15–20% given scale.\u003c\/p\u003e\n\u003cp\u003eEstablished protocols and automated high-throughput platforms drive low unit costs; Quest operates ~2,200 patient service centers and dozens of labs, keeping gross margins for routine testing notably above company average.\u003c\/p\u003e\n\u003cp\u003eQuest milks this cash cow via maintenance capex, process optimization, and volume pricing, supporting predictable free cash flow and funding growth areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-margin, mature segment\u003c\/li\u003e\n\u003cli\u003eAutomated, high-throughput systems\u003c\/li\u003e\n\u003cli\u003e~15–20% revenue contribution estimate\u003c\/li\u003e\n\u003cli\u003e~2,200 service centers scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuest's core lab trio: $6.2B cash cows, 18–20% margins, steady FCF for $1.02B payouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore lab testing, workplace drug screens, and physician-office services are Quest Diagnostics cash cows: combined they drove ~ $6.2B revenue and ~18–20% adjusted operating margin in 2024–25, produced steady FCF used for $1.02B dividends\/debt service (2024), and show low growth (~2% CAGR) but high share (25–35%), so reinvestment targets efficiency and retention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (core segments)\u003c\/td\u003e\n\u003ctd\u003e$6.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. op margin\u003c\/td\u003e\n\u003ctd\u003e18–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e25–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth\u003c\/td\u003e\n\u003ctd\u003e~2% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividends\/debt service\u003c\/td\u003e\n\u003ctd\u003e$1.02B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eQuest Diagnostics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Quest Diagnostics BCG Matrix you'll receive after purchase—no watermarks, no demo content, just a fully formatted, analysis-ready report tailored for strategic clarity and professional use. This exact document reflects market-backed positioning and clear quadrant insights; once bought, the full version is delivered instantly to your inbox for editing, printing, or presenting to stakeholders. No surprises—just a polished, ready-to-use strategic asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747672076665,"sku":"questdiagnostics-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/questdiagnostics-bcg-matrix.png?v=1772200836","url":"https:\/\/growthsharematrix.com\/products\/questdiagnostics-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}